Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its price objective boosted by stock analysts at Wedbush from $30.00 to $38.00 in a research note issued on Monday, The Fly reports. Wedbush’s price objective would suggest a potential upside of 46.15% from the stock’s current price.
Several other research firms have also commented on KNSA. BidaskClub raised shares of Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, April 29th. JPMorgan Chase & Co. boosted their target price on shares of Kiniksa Pharmaceuticals from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Wednesday, March 11th. Bank of America assumed coverage on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 1st. They set a “buy” rating and a $25.00 target price for the company. ValuEngine raised shares of Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, March 30th. Finally, Zacks Investment Research raised shares of Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research note on Thursday, April 23rd. Nine equities research analysts have rated the stock with a buy rating, Kiniksa Pharmaceuticals has an average rating of “Buy” and an average target price of $31.14.
NASDAQ KNSA opened at $26.00 on Monday. Kiniksa Pharmaceuticals has a one year low of $5.01 and a one year high of $28.67. The company has a 50-day simple moving average of $22.21 and a 200-day simple moving average of $17.52. The firm has a market capitalization of $1.55 billion, a PE ratio of -11.66 and a beta of -0.02.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, April 28th. The company reported ($0.48) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.15. Equities research analysts expect that Kiniksa Pharmaceuticals will post -2.31 earnings per share for the current year.
In other Kiniksa Pharmaceuticals news, EVP Thomas W. Beetham sold 13,752 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $25.07, for a total transaction of $344,762.64. Following the sale, the executive vice president now directly owns 43,341 shares in the company, valued at approximately $1,086,558.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Thomas W. Beetham sold 47,423 shares of the business’s stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $19.06, for a total transaction of $903,882.38. Following the sale, the executive vice president now owns 32,107 shares in the company, valued at $611,959.42. The disclosure for this sale can be found here. 59.92% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the business. Foresite Capital Management IV LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the 1st quarter worth about $1,006,000. Vivo Capital LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the 1st quarter worth approximately $11,750,000. Two Sigma Investments LP raised its holdings in shares of Kiniksa Pharmaceuticals by 3.2% in the 1st quarter. Two Sigma Investments LP now owns 18,789 shares of the company’s stock worth $291,000 after purchasing an additional 578 shares in the last quarter. Atom Investors LP bought a new stake in shares of Kiniksa Pharmaceuticals in the 1st quarter worth approximately $2,991,000. Finally, Ikarian Capital LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the 1st quarter worth approximately $5,556,000. Institutional investors own 31.79% of the company’s stock.
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Featured Article: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.